JPWO2019166822A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019166822A5 JPWO2019166822A5 JP2020544266A JP2020544266A JPWO2019166822A5 JP WO2019166822 A5 JPWO2019166822 A5 JP WO2019166822A5 JP 2020544266 A JP2020544266 A JP 2020544266A JP 2020544266 A JP2020544266 A JP 2020544266A JP WO2019166822 A5 JPWO2019166822 A5 JP WO2019166822A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- alkyl
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 25
- 239000011780 sodium chloride Substances 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 6
- 206010057668 Cognitive disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 102000003678 AMPA Receptors Human genes 0.000 claims 2
- 108090000078 AMPA Receptors Proteins 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010012378 Depression Diseases 0.000 claims 2
- 206010012401 Depressive disease Diseases 0.000 claims 2
- 208000004559 Hearing Loss Diseases 0.000 claims 2
- 206010011879 Hearing loss Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 2
- 206010028003 Motor neurone disease Diseases 0.000 claims 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- 206010064062 Neurodevelopmental disease Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010038678 Respiratory depression Diseases 0.000 claims 2
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 2
- 201000008779 central nervous system disease Diseases 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000002964 excitative Effects 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000008895 mood disease Diseases 0.000 claims 2
- 230000000926 neurological Effects 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 230000003956 synaptic plasticity Effects 0.000 claims 2
- 230000005062 synaptic transmission Effects 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803340.7A GB201803340D0 (en) | 2018-03-01 | 2018-03-01 | Compounds |
| GB1803340.7 | 2018-03-01 | ||
| PCT/GB2019/050578 WO2019166822A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515749A JP2021515749A (ja) | 2021-06-24 |
| JPWO2019166822A5 true JPWO2019166822A5 (pt) | 2022-02-25 |
| JP7225255B2 JP7225255B2 (ja) | 2023-02-20 |
Family
ID=61903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544266A Active JP7225255B2 (ja) | 2018-03-01 | 2019-03-01 | Ａｍｐａ受容体機能を調節する化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11298345B2 (pt) |
| EP (1) | EP3759092B1 (pt) |
| JP (1) | JP7225255B2 (pt) |
| KR (1) | KR20200128032A (pt) |
| CN (1) | CN112004811B (pt) |
| AU (1) | AU2019226718C1 (pt) |
| BR (1) | BR112020017739A2 (pt) |
| CA (1) | CA3091783A1 (pt) |
| DK (1) | DK3759092T3 (pt) |
| ES (1) | ES2970784T3 (pt) |
| FI (1) | FI3759092T3 (pt) |
| GB (1) | GB201803340D0 (pt) |
| MX (1) | MX2020009097A (pt) |
| PL (1) | PL3759092T3 (pt) |
| RU (1) | RU2020127537A (pt) |
| WO (1) | WO2019166822A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| US6949571B2 (en) * | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| WO2004046137A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| MX2007012635A (es) | 2005-04-12 | 2008-01-11 | Vicore Pharma Ab | Nuevos agonistas de angiotensina ii triciclica. |
| EA200802007A1 (ru) | 2006-03-20 | 2009-02-27 | Глэксо Груп Лимитед | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине |
| DK2049475T3 (da) | 2006-04-24 | 2012-03-05 | Lilly Co Eli | Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1 |
| DE602007013450D1 (de) | 2006-11-03 | 2011-05-05 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711088D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| AR067673A1 (es) | 2007-07-26 | 2009-10-21 | Vitae Pharmaceuticals Inc | Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas. |
| KR20100063087A (ko) | 2007-09-20 | 2010-06-10 | 코텍스 파마슈티칼스, 인크. | 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논 |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| AR071236A1 (es) | 2008-05-01 | 2010-06-02 | Vitae Pharmaceuticals Inc | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2018
- 2018-03-01 GB GBGB1803340.7A patent/GB201803340D0/en not_active Ceased
-
2019
- 2019-03-01 AU AU2019226718A patent/AU2019226718C1/en active Active
- 2019-03-01 JP JP2020544266A patent/JP7225255B2/ja active Active
- 2019-03-01 EP EP19710107.4A patent/EP3759092B1/en active Active
- 2019-03-01 MX MX2020009097A patent/MX2020009097A/es unknown
- 2019-03-01 WO PCT/GB2019/050578 patent/WO2019166822A1/en active Application Filing
- 2019-03-01 CA CA3091783A patent/CA3091783A1/en active Pending
- 2019-03-01 FI FIEP19710107.4T patent/FI3759092T3/fi active
- 2019-03-01 RU RU2020127537A patent/RU2020127537A/ru unknown
- 2019-03-01 US US16/970,394 patent/US11298345B2/en active Active
- 2019-03-01 KR KR1020207025799A patent/KR20200128032A/ko unknown
- 2019-03-01 DK DK19710107.4T patent/DK3759092T3/da active
- 2019-03-01 PL PL19710107.4T patent/PL3759092T3/pl unknown
- 2019-03-01 BR BR112020017739-3A patent/BR112020017739A2/pt unknown
- 2019-03-01 ES ES19710107T patent/ES2970784T3/es active Active
- 2019-03-01 CN CN201980016394.0A patent/CN112004811B/zh active Active
-
2022
- 2022-03-04 US US17/687,296 patent/US20230000847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10618929B2 (en) | 3-substituted 5-amino-6H-thiazolo[4,5-D]pyrimidine-2, 7-dione compounds for the treatment and prophylaxis of virus infection | |
| CN107592864B (zh) | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 | |
| US20180118763A1 (en) | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | |
| JP2020502092A5 (pt) | ||
| EP3119755B1 (en) | Antifungal compound process | |
| JP6298765B2 (ja) | 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物 | |
| CA3012832A1 (en) | N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1 | |
| JP6509897B2 (ja) | 抗真菌化合物の調製方法 | |
| JP2018523665A5 (pt) | ||
| KR101886945B1 (ko) | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 | |
| JP2017514790A (ja) | 抗真菌化合物の調製方法 | |
| JP2013536833A5 (pt) | ||
| EA031041B1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| JP2020504156A5 (pt) | ||
| AU2017207991A1 (en) | Pyridazine derivatives as EAAT2 activators | |
| AU2016353348A1 (en) | Heterocyclic compounds for the treatment of disease | |
| JP7065989B2 (ja) | インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物 | |
| JP2018508494A (ja) | 新規シクロプロパベンゾフラニルピリドピラジンジオン | |
| RU2020127537A (ru) | Соединения, которые модулируют функцию ampa-рецептора | |
| AU2017301767A1 (en) | Compounds and compositions and uses thereof | |
| JPWO2019166822A5 (pt) | ||
| JP2008515884A (ja) | 新規なヒドロキシメチルベンゾチアゾールアミド | |
| JP2015505536A5 (pt) | ||
| JP6268656B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| WO2018211324A1 (en) | Prodrugs for the treatment of disease |